TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Alphamab Oncology ( (HK:9966) ) is now available.
Alphamab Oncology announced that its drug JSKN003 has been granted Orphan Drug Designation by the U.S. FDA for treating gastric cancer and gastroesophageal junction cancer. This designation will support Alphamab’s efforts in research, development, and commercialization in the U.S., potentially offering benefits like funding, tax credits, and market exclusivity. The announcement marks a significant step in addressing the global health challenge posed by these cancers and enhances Alphamab’s position in the oncology sector.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China, specializing in antibody-drug conjugates (ADCs), bispecific antibodies, and multi-functional protein engineering. The company has a robust pipeline of oncology-focused products, including ADCs and monoclonal antibodies, with one product approved for marketing in China and several others in advanced clinical trial stages.
Average Trading Volume: 4,090,971
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.9B
For detailed information about 9966 stock, go to TipRanks’ Stock Analysis page.